Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective 4-arm pilot dose-finding study of P.L.E.A.S.E. plus topical imiquimod versus standard topical imiquimod in basal cell carcinoma
2010-022521-15Phase 2Completed
- Sponsor
- Pantec Biosolutions AG
- Start
- Sep 2010
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of imiquimod in basal cell carcinoma (BCC) (4 arms), sponsored by Pantec Biosolutions AG. Primary endpoint: Primary aldara therapeutic effect at week 3. Started Sep 2010; status: completed.
02
Drugs
imiquimod
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2010-022521-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022521-15.